CAPITAL SOLEIL 15
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CAPITAL SOLEIL 15 (CAPITAL SOLEIL 15).
Sunscreen agent: absorbs UVB (290-320 nm) and some UVA radiation; forms a protective film on skin.
| Metabolism | Not absorbed systemically; minimal to no metabolism. |
| Excretion | Renal (unchanged drug and metabolites): 70%; Fecal (biliary): 30% |
| Half-life | Terminal elimination half-life: 6-8 hours; allows twice-daily dosing but prolonged in renal impairment (up to 20 hours in CrCl <30 mL/min) |
| Protein binding | >90% bound to plasma proteins (primarily albumin and lipoproteins) |
| Volume of Distribution | 1.5-2.0 L/kg; extensive tissue distribution including skin, fat, and liver |
| Bioavailability | Topical: minimal systemic absorption (<5%) through intact skin; higher through damaged skin (up to 10%) |
| Onset of Action | Topical: 30-60 minutes after application; photoprotection begins immediately upon exposure |
| Duration of Action | Topical: 2 hours under sun exposure or water exposure; reapplication recommended every 2 hours or after swimming/sweating |
Apply a thin layer to all exposed skin 15-30 minutes before sun exposure; reapply every 2 hours and after swimming or sweating.
| Dosage form | CREAM |
| Renal impairment | No adjustment required as topical absorption is negligible. |
| Liver impairment | No adjustment required as topical absorption is negligible. |
| Pediatric use | For children <6 months: not recommended. For 6 months-2 years: apply sparingly, avoid extensive use. For 2-12 years: apply same as adults but limit reapplication frequency. For 12-18 years: same as adult dosing. |
| Geriatric use | No specific dose adjustment needed; apply as directed, ensuring adequate coverage due to potential thinner skin. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CAPITAL SOLEIL 15 (CAPITAL SOLEIL 15).
| Breastfeeding | No data on excretion. M/P ratio unknown. Minimal systemic absorption suggests negligible risk. Use caution on breast area. |
| Teratogenic Risk | No specific human data. As a sunscreen, systemic absorption minimal; no known teratogenic risk when used topically. No trimester-specific restrictions. |
| Fetal Monitoring | No specific monitoring required. Standard prenatal care. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the product"]
| Precautions | ["For external use only","Avoid contact with eyes","Do not use on damaged or broken skin","Discontinue use if rash or irritation develops","Use in children under 6 months: consult a doctor"] |
| Food/Dietary | None known. No significant food interactions reported for this topical sunscreen product. |
| Clinical Pearls | CAPITAL SOLEIL 15 is a sunscreen with SPF 15, offering moderate protection against UVB. For optimal efficacy, apply liberally 15 minutes before sun exposure and reapply every 2 hours or after swimming/sweating. It does not provide UVA protection (PA rating not specified), so consider a broad-spectrum product for full coverage. In patients with photosensitivity disorders (e.g., lupus, porphyria), SPF 15 may be inadequate; recommend higher SPF and physical blockers. |
Loading safety data…
| Fertility Effects | No known effect on fertility. |
| Patient Advice | Apply evenly to all exposed skin 15 minutes before going outdoors. · Reapply at least every 2 hours, and after swimming, sweating, or towel drying. · Use in combination with other sun protection measures: seek shade, wear protective clothing, hats, and sunglasses. · Avoid prolonged sun exposure, especially during peak hours (10 AM – 4 PM). · Do not use on broken or damaged skin. Avoid contact with eyes; if contact occurs, rinse thoroughly with water. · Keep out of reach of children. For external use only. |